Prasad G. Kamble

Prasad G. Kamble

Auto-generated profile, based on publicly available information

Prasad G. Kamble

Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
MPMaria Pereira
Maria Pereira
KTKetan Thombare
Ketan Thombare
ASAssel Sarsenbayeva
Assel Sarsenbayeva
PKPrasad G. Kamble
Prasad G. Kamble
KAKristina Almby
Kristina Almby
JEJan W. Eriksson
Jan W. Eriksson

17 November 2016 in Endocrine
Verified
Journal Article
Open access
PDF file
CSCherno O. Sidibeh
Cherno O. Sidibeh
MPMaria Pereira
Maria Pereira
JBJoey Lau Börjesson
Joey Lau Börjesson
PKPrasad G. Kamble
Prasad G. Kamble
SSStanko Skrtic
Stanko Skrtic
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
We recently showed that the peripheral cannabinoid receptor type 1 (CNR1) gene is upregulated by the synthetic glucocorticoid dexamethasone. CNR1 is highly expressed in the central nervous system and has been a drug target for the treatment of obesity. Here we explore the role of peripheral CNR1 in states of insulin resistance in human adipose tissue. Subcutaneous adipose tissue was obtained from well-controlled type 2 diabetes subjects and controls. Subcutaneous adipose tissue gene expression levels of CNR1 and endocannabinoid synthesizing and degrading enzymes were assessed. Furthermore, paired human subcutaneous adipose tissue and omental adipose tissue from non-diabetic volunteers undergoing kidney donation or bariatric surgery, was incubated with or without dexamethasone. Subcutaneous adipose tissue obtained from volunteers through needle biopsy was incubated with or without dexamethasone and in the presence or absence of the CNR1-specific antagonist AM281. CNR1 gene and protein expression, lipolysis and glucose uptake were evaluated. Subcutaneous adipose tissue CNR1 gene expression levels were 2-fold elevated in type 2 diabetes subjects compared with control subjects. Additionally, gene expression levels of CNR1 and endocannabinoid-regulating enzymes from both groups correlated with markers of insulin resistance. Dexamethasone increased CNR1 expression dose-dependently in subcutaneous adipose tissue and omental adipose tissue by up to 25-fold. Dexamethasone pre-treatment of subcutaneous adipose tissue increased lipolysis rate and reduced glucose uptake. Co-incubation with the CNR1 antagonist AM281 prevented the stimulatory effect on lipolysis, but had no effect on glucose uptake. CNR1 is upregulated in states of type 2 diabetes and insulin resistance. Furthermore, CNR1 is involved in glucocorticoid-regulated lipolysis. Peripheral CNR1 could be an interesting drug target in type 2 diabetes and dyslipidemia.

23 February 2021 in Obesity
Verified
Journal Article
Open access
PDF file
PKPetros Katsogiannos
Petros Katsogiannos
PKPrasad G. Kamble
Prasad G. Kamble
MPMaria J. Pereira
Maria J. Pereira
MSMagnus Sundbom
Magnus Sundbom
PCPer‐Ola Carlsson
Per‐Ola Carlsson
DEDaniel Espes
Daniel Espes
Objective: This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux‐en‐Y gastric bypass (RYGB) with healthy controls.Methods: A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m2 were compared with 25 healthy controls without obesity. Cytokines, adipokines, and peptides of relevance for inflammation and metabolism were analyzed in plasma.Results: Significant decreases in weight and glycated hemoglobin A1c were observed. At baseline, interleukin‐6 (IL‐6), IFN‐β, IL‐18, leptin, and hepatocyte growth factor were higher in all patients with obesity compared with healthy controls. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, and visfatin were also increased, whereas bone morphogenic protein‐4 was decreased. Following RYGB, IL‐6 and hepatocyte growth factor were still increased in both groups compared with controls. In T2D patients, IFN‐β, IL‐27, IL‐1α, IL‐2, regenerating islet‐derived protein 3A, visfatin, and osteopontin were found to be increased. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, leptin, and visfatin remained increased.Conclusions: The altered cytokine profile of patients with obesity persisted after RYGB despite large weight loss and improved metabolic status, thus reflecting an inherent inflammatory state.

1 May 2016 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
PKPrasad G. Kamble
Prasad G. Kamble
MPMaria Pereira
Maria Pereira
CSCherno O. Sidibeh
Cherno O. Sidibeh
SASam Amini
Sam Amini
MSMagnus Sundbom
Magnus Sundbom
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson

23 January 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PKPetros Katsogiannos
Petros Katsogiannos
PKPrasad G Kamble
Prasad G Kamble
GBGretha J Boersma
Gretha J Boersma
FKF Anders Karlsson
F Anders Karlsson
PLPer Lundkvist
Per Lundkvist
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
Context Roux-en-Y gastric bypass (RYGB) surgery effectively prevents or treats type 2 diabetes (T2D). Adipose tissue (AT) mechanisms may be of importance. Objective To assess the relationship between early changes in whole-body and AT metabolism in surgically treated patients with T2D. Design and Setting A randomized single-center study. Patients Nineteen patients with T2D with body mass index 30 to 45 kg/m2. Interventions Thirteen patients were assessed at baseline and 4 and 24 weeks after RYGB (preceded by a 4-week low-calorie diet) and compared with 6 control patients continuing standard medical treatment: oral glucose tolerance test, subcutaneous AT biopsies for gene expression, adipocyte size, glucose uptake, lipolysis, and insulin action. Results At 4 and 24 weeks post-RYGB, all patients but one had stopped diabetes medication. Fasting glucose, HbA1c, and insulin levels decreased and the Matsuda index increased compared with baseline (P < 0.01 for all), indicating improved whole-body insulin sensitivity. Mean adipocyte size significantly reduced, more at 4 than at 24 weeks; at 4 weeks, glucose uptake per adipocyte was lowered, and isoproterenol-stimulated lipolysis tended to increase, whereas the fold insulin effects on glucose uptake and lipolysis were unchanged. Expression of genes involved in fatty acid oxidation, CPT1b and adiponectin, was increased at 4 weeks, whereas leptin and E2F1 (involved in cell proliferation) were reduced (P < 0.05 for all). Conclusion Glycemic control and in vivo insulin sensitivity improved 4 weeks after RYGB, but adipocyte insulin sensitivity did not change despite a marked reduction in adipocyte size. Thus, mechanisms for a rapid improvement of T2D after RYGB may occur mainly in other tissues than adipose.

26 November 2020 in Diabetologia
Verified
Journal Article
Open access
PDF file
MLMartin H. Lundqvist
Martin H. Lundqvist
KAKristina Almby
Kristina Almby
UWUrban Wiklund
Urban Wiklund
NANiclas Abrahamsson
Niclas Abrahamsson
PKPrasad G. Kamble
Prasad G. Kamble
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
Aims/hypothesis: Results from animal models and some clinical work suggest a role for the central nervous system (CNS) in glucose regulation and type 2 diabetes pathogenesis by modulation of glucoregulatory hormones and the autonomic nervous system (ANS). The aim of this study was to characterise the neuroendocrine response to various glucose concentrations in overweight and insulin-resistant individuals compared with lean individuals. Methods: Overweight/obese (HI, n = 15, BMI ≥27.0 kg/m2) and lean (LO, n = 15, BMI <27.0 kg/m2) individuals without diabetes underwent hyperinsulinaemic euglycaemic–hypoglycaemic clamps and hyperglycaemic clamps on two separate occasions with measurements of hormones, Edinburgh Hypoglycaemic Symptom Scale (ESS) score and heart rate variability (HRV). Statistical methods included groupwise comparisons with Mann–Whitney U tests, multilinear regressions and linear mixed models between neuroendocrine responses and continuous metabolic variables. Results: During hypoglycaemic clamps, there was an elevated cortisol response in HI vs LO (median ΔAUC 12,383 vs 4793 nmol/l × min; p = 0.050) and a significantly elevated adrenocorticotropic hormone (ACTH) response in HI vs LO (median ΔAUC 437.3 vs 162.0 nmol/l × min; p = 0.021). When adjusting for clamp glucose levels, obesity (p = 0.033) and insulin resistance (p = 0.009) were associated with elevated glucagon levels. By contrast, parasympathetic activity was less suppressed in overweight individuals at the last stage of hypoglycaemia compared with euglycaemia (high-frequency power of HRV, p = 0.024). M value was the strongest predictor for the ACTH and PHF responses, independent of BMI and other variables. There was a BMI-independent association between the cortisol response and ESS score response (p = 0.024). During hyperglycaemic clamps, overweight individuals displayed less suppression of glucagon levels (median ΔAUC −63.4% vs −73.0%; p = 0.010) and more suppression of sympathetic relative to parasympathetic activity (low-frequency/high-frequency power, p = 0.011). Conclusions/interpretation: This study supports the hypothesis that altered responses of insulin-antagonistic hormones and the ANS to glucose fluctuations occur in overweight and insulin-resistant individuals, and that these responses are probably partly mediated by the CNS. Their potential role in development of type 2 diabetes needs to be addressed in future research.